In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Europe United States

How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees

Executive Summary

Biotech executives make strategic decisions based on incentives that aren't necessarily aligned to benefit either the company's investors or employees. Three modifications to business as usual would help solve the problem and lead to improvements in the productivity of people and capital in the sector.
Table

View full table

Advertisement

Related Content

In Vivo
Solution Development: A Model For Structuring Biotechs And Developing Better Drugs
In Vivo
The Alnylam Turnaround: What Changed Investors’ Minds?
In Vivo
Your First Drug's Approved and Launched...Now What?
In Vivo
Valeant's Hostile Bid For Cephalon
In Vivo
Valeant's Hostile Bid For Cephalon
In Vivo
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
In Vivo
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Scrip
Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns
In Vivo
Despite Celgene's Abraxane Stock, Trading Earn-Outs Is The Exception Not The Rule
In Vivo
Despite Celgene's Abraxane Stock, Trading Earn-Outs Is The Exception Not The Rule

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical Europe United States
UsernamePublicRestriction

Register

IV003671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By